Cardona GMC, Martínez LCI, Ramírez BJD

Idioma: Español
Referencias bibliográficas: 37
Paginas: 243-252
Archivo PDF: 452.42 Kb.

RESUMEN

La paracoccidioidomicosis es la micosis profunda más frecuente en América Latina. Afecta principalmente a los adultos y produce lesiones crónicas en la piel, las mucosas y los pulmones. El diagnóstico se basa en la demostración de levaduras con gemación múltiple en las muestras clínicas y mediante cultivo para demostrar su dimorfismo. Los casos reportados se han incrementado en parte por enfermedades como el SIDA y por el advenimiento de nuevas terapias inmunosupresoras. En este artículo reportamos el cuadro clínico de un paciente con artritis reumatoide en un estado avanzado y que sin terapia moduladora para su enfermedad de base presenta paracoccidioidomicosis aguda/subaguda.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Restrepo A, Tobón A. Paracoccidioides Brasiliensis. In Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia: Churchill Livingstone. 2009; 3357-3363.

2. Londero A, Ramos C. Paracoccidioidomicosis: estudio clínico-5. micológico de 260 casos observados no interior do Estado do Rio Grande do Sul. J Pneumol 1990; 16: 129-132.

3. Cadavid D, Restrepo A. Factors associated with Paracoccidiodes brasiliensis infection among permanent residents of three endemic areas in Colombia. Epidemiol Infect 1993; 111: 121-133.

4. Tobón AM, Agudelo CA, Restrepo CA, et al. Adrenal function status in patients with paracoccidioidomycosis after prolonged post-therapy follow- up. Am J Trop Med Hyg 2010; 83: 111-114.

5. Zaputovich F, Cardozo L, Di Martino B. Paracoccidioidomicosis en paciente HIV. Rev Esp Patol 2008; 41: 150-153.

6. Theodoro RC, Bagagli E, Oliveira C. Phylogenetic analysis of PRP8 intein in Paracoccidioides brasiliensis species complex. Fungal Genet Biol 2008; 45: 1284-1291.

7. Calle D, Rosero DS, Orozco LC, Camargo D, Castaneda E, Restrepo A. Paracoccidioidomycosis in Colombia: an ecological study. Epidemiol Infect 2001; 126: 309-315.

8. Coutinho ZF, Silva D, Lazera M, et al. Paracoccidioidomycosis mortality in Brazil (1980-1995). Cad Saude Publica 2002; 18: 1441-1454.

9. Restrepo A, McEwen JG, Castaneda E. The habitat of Paracoccidioides brasiliensis: how far from solving the riddle? Med Mycol 2001; 39: 233-241.

10. Benard G, Kavakama J, Mendes-Giannini MJ, Kono A, Duarte AJ, Shikanai-Yasuda MA. Contribution to the natural history of paracoccidioidomycosis: identification of the primary pulmonary infection in the severe acute form of the disease--a case report. Clin Infect Dis 2005; 40: e1-e4.

11. Restrepo A. Morphological aspects of Paracoccidioides brasiliensis in lymph nodes: implications for the prolonged latency of paracoccidioidomycosis? Med Mycol 2000; 38: 317-322.

12. Travassos LR, Taborda CP, Colombo AL. Treatment options for paracoccidioidomycosis and new strategies investigated. Expert Rev Anti Infect Ther 2008; 6: 251-262.

13. Pereira RM, Bucaretchi F, Barison Ede M, Hessel G, Tresoldi AT. Paracoccidioidomycosis in children: clinical presentation, follow-up and outcome. Rev Inst Med Trop Sao Paulo 2004; 46: 127-131.

14. Restrepo A, Benard G, de Castro CC, Agudelo CA, Tobon AM. Pulmonary paracoccidioidomycosis. Semin Respir Crit Care Med 2008; 29: 182-197.

15. Colombo AL, Faical S, Kater CE. Systematic evaluation of the adrenocortical function in patients with paracoccidioidomycosis. Mycopathologia 1994; 127: 89-93.

16. Amstalden EM, Xavier R, Kattapuram SV, Bertolo MB, Swartz MN, Rosenberg AE. Paracoccidioidomycosis of bones and joints. A clinical, radiologic, and pathologic study of 9 cases. Medicine (Baltimore) 1996; 75: 213-225.

17. Severo LC, Kauer CL, Oliveira F, Rigatti RA, Hartmann AA, Londero AT. Paracoccidioidomycosis of the male genital tract. Report of eleven cases and a review of Brazilian literature. Rev Inst Med Trop Sao Paulo 2000; 42: 38-40.

18. Tobon AM, Agudelo CA, Osorio ML, et al. Residual pulmonary abnormalities in adult patients with chronic paracoccidioidomycosis: prolonged follow-up after itraconazole therapy. Clin Infect Dis 2003; 37: 898-904.

19. Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: an update. Clin Microbiol Rev 1993; 6: 89-117.

20. de Camargo ZP. Serology of paracoccidioidomycosis. Mycopathologia 2008; 165: 289-302.

21. Marques da Silva SH, Queiroz-Telles F, Colombo AL, Blotta MH, Lopes JD, Pires De Camargo Z. Monitoring gp43 antigenemia in Paracoccidioidomycosis patients during therapy. J Clin Microbiol 2004; 42: 2419-2424.

22. Gomes GM, Cisalpino PS, Taborda CP, de Camargo ZP. PCR for diagnosis of paracoccidioidomycosis. J Clin Microbiol 2000; 38: 3478-3480.

23. Menezes V, Soares B, Fontes C. Drugs for treating paracoccidioidomycosis. Cochrane Database Syst Rev 2006; 19: CD004967.

24. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997; 52: 235-237.

25. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997; 37:535-540.

26. Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995; 39: 1671-1675.

27. Queiroz-Telles F, Goldani LZ, Schlamm HT, Goodrich JM, Espinel-Ingroff A, Shikanai- Yasuda MA. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007; 45: 1462-1469.

28. Morejon KM, Machado AA, Martinez R. Paracoccidioidomycosis in patients infected with and not infected with human immunodeficiency virus: a case-control study. Am J Trop Med Hyg 2009; 80: 359-366.

29. de Camargo ZP, de Franco MF. Current knowledge on pathogenesis and immunodiagnosis of paracoccidioidomycosis. Rev Iberoam Micol 2000; 17: 41-48.

30. Gonzalez A, Sahaza JH, Ortiz BL, Restrepo A, Cano LE. Production of pro-inflammatory cytokines during the early stages of experimental Paracoccidioides brasiliensis infection. Med Mycol 2003; 41: 391-399.

31. Mamoni RL, Nouer SA, Oliveira SJ, et al. Enhanced production of specific IgG4, IgE, IgA and TGF-beta in sera from patients with the juvenile form of paracoccidioidomycosis. Med Mycol 2002; 40: 153-159.

32. Aguado MT, Lambris JD, Tsokos GC, et al. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. J Clin Invest 1985; 76: 1418-1426.

33. Karhawi AS, Colombo AL, Salomao R. Production of IFN-gamma is impaired in patients with paracoccidioidomycosis during active disease and is restored after clinical remission. Med Mycol 2000; 38: 225-229.

34. Sugar AM, Restrepo A, Stevens DA. Paracoccidioidomycosis in the immunosuppressed host: report of a case and review of the literature. Am Rev Respir Dis 1984; 129: 340-342.

35. Kashino SS, Fazioli RA, Cafalli-Favati C, et al. Resistance to Paracoccidioides brasiliensis infection is linked to a preferential Th1 immune response, whereas susceptibility is associated with absence of IFN-gamma production. J Interferon Cytokine Res 2000; 20: 89-97.

36. Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol 1990; 9: 100-110.

37. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903-911.